论文部分内容阅读
目的 :评价靶向性非病毒载体系统介导的 p2 1WAF1对人喉癌基因治疗的可行性和有效性。方法 :利用组建的表皮生长因子受体 (EGF R)介导的多肽基因导入系统与p2 1WAF1基因构成基因载体复元物 ,分别体外转染人喉癌Hep 2细胞 ,通过荧光显微镜观察和通过转染喉癌细胞生长曲线及流式细胞仪检测等方法观察新的受体介导多肽基因导入系统对外源基因的导入和导入后对人喉癌细胞的抑制作用。结果 :荧光显微镜观察到标记基因的表达产物绿色荧光蛋白 ,转染后 4 8h呈弱阳性 ,72h呈强阳性 ;p2 1WAF1基因转染后喉癌细胞生长受到明显抑制 ,第 4天抑制率为 79% ;流式细胞仪检测到p2 1WAF1转染的Hep 2细胞发生了明显的凋亡。结论 :EGF R介导的多肽基因导入系统可靶向性地将治疗基因导入Hep 2人喉癌细胞 ,p2 1WAF1基因可明显抑制Hep 2细胞的生长并有效诱导基因凋亡。
PURPOSE: To evaluate the feasibility and effectiveness of targeting non-viral vector-mediated p21WAF1 gene therapy in human laryngeal cancer. Methods: The EGFR-mediated gene delivery system and the p2 1WAF1 gene were used to construct the gene vector complex and transfected into human laryngeal carcinoma Hep 2 cells in vitro respectively. The cells were transfected with Hep 2 cells by fluorescence microscopy and transfection Laryngeal cancer cell growth curve and flow cytometry and other methods to observe the new receptor-mediated polypeptide gene introduction system for foreign gene introduction and introduction of human laryngeal carcinoma cells after inhibition. Results: The green fluorescent protein (EGFP) was detected by fluorescence microscopy. The expression was weakly positive 48 h after transfection and strongly positive at 72 h after transfection. The growth of laryngeal carcinoma cells was significantly inhibited after p2 1WAF1 gene transfection, and the inhibition rate was 79 %; Flow cytometry detected p2 1WAF1 transfected Hep 2 cells were significantly apoptosis. CONCLUSION: EGFR-mediated gene delivery system can target gene therapy to Hep 2 human laryngeal carcinoma cells. The p2 1WAF1 gene can significantly inhibit the growth of Hep 2 cells and induce apoptosis effectively.